Benzinga | Aug 6, 2021 07:41AM EDT

Twist Bioscience Raises FY21 Sales Guidance From Sales $121M-$129M To $129M-$132M vs $127.12M Est.

Updated Fiscal 2021 Financial Guidance

The following statements are based on Twist's current expectations for fiscal 2021. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. Twist does not plan to update, nor does it undertake any obligation to update, this outlook in the future.

For the full fiscal year 2021, Twist provided the following updated financial guidance:

* Increasing revenue guidance, which is now expected to be in the range of $129 million to $132 million Synbio revenue including Ginkgo Bioworks is expected to be in the range of $54 to $56 million NGS revenue is estimated to be in the range of $69 to $70 million Biopharma revenue is estimated to be approximately $6 million

* Gross margin is expected to be 38% to 40% for fiscal 2021

* Operating expenses including R&D and SG&A are expected to be $200 million for the year

* Net loss is expected to be approximately $150 million, reflecting our increased investments in our commercial organization and research and development activities R&D is expected to be approximately $70 million Stock-based compensation is expected to be approximately $37 million Depreciation is expected to be $10 million Capital expenditures are expected to be $40 million, including expansion into "Factory of the Future"